Key Action Statement Profile: KAS 4C
| Aggregate evidence quality | Grade B |
| Benefits | Identify children who may have AOM caused by pathogens resistant to previous antibiotics. |
| Risks, harms, cost | Cost. Time for patient and clinician to make change. Potential need for parenteral medication. |
| Benefit-harm assessment | Preponderance of benefit. |
| Value judgments | None. |
| Intentional vagueness | “Reassess” is not defined. The clinician may determine the method of assessment. |
| Role of patient preferences | Limited. |
| Exclusions | Appearance of TM improved. |
| Strength | Recommendation |
| Aggregate evidence quality | Grade B |
| Benefits | Identify children who may have AOM caused by pathogens resistant to previous antibiotics. |
| Risks, harms, cost | Cost. Time for patient and clinician to make change. Potential need for parenteral medication. |
| Benefit-harm assessment | Preponderance of benefit. |
| Value judgments | None. |
| Intentional vagueness | “Reassess” is not defined. The clinician may determine the method of assessment. |
| Role of patient preferences | Limited. |
| Exclusions | Appearance of TM improved. |
| Strength | Recommendation |